Cargando…

Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review

BACKGROUND: Despite the burden of schizophrenia and bipolar disorder in the Chinese population, country-specific data to guide practitioners regarding antipsychotic therapy are lacking. The primary aim of this systematic review was to examine evidence of the efficacy, effectiveness, and safety of ol...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Hai Bo Haber, Liu, Li, Zhang, Hena, Montgomery, William, Treuer, Tamás
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037301/
https://www.ncbi.nlm.nih.gov/pubmed/24876777
http://dx.doi.org/10.2147/NDT.S58096
_version_ 1782318237194649600
author Xue, Hai Bo Haber
Liu, Li
Zhang, Hena
Montgomery, William
Treuer, Tamás
author_facet Xue, Hai Bo Haber
Liu, Li
Zhang, Hena
Montgomery, William
Treuer, Tamás
author_sort Xue, Hai Bo Haber
collection PubMed
description BACKGROUND: Despite the burden of schizophrenia and bipolar disorder in the Chinese population, country-specific data to guide practitioners regarding antipsychotic therapy are lacking. The primary aim of this systematic review was to examine evidence of the efficacy, effectiveness, and safety of olanzapine in Chinese populations. METHODS: A systematic literature search was conducted using databases covering international and Chinese core journals using search terms related to schizophrenia and bipolar disorder, specified countries (People’s Republic of China, Hong Kong, Taiwan), and olanzapine treatment. Following initial screening, inclusion and exclusion criteria were applied to the search results to identify relevant studies from which data were extracted. RESULTS: A total of 489 publications were retrieved and 61 studies were identified for inclusion. Most studies were related to schizophrenia (n=54), with six studies related to bipolar disorder and one study related to both conditions. The quality of study methods and reporting in international journals was noticeably better than in Chinese language journals. Most studies included relatively small patient populations and were of short duration. The efficacy of olanzapine in Chinese populations was confirmed by multiple comparative and noncomparative studies that found statistically significant reductions in symptom measures in studies conducted for ≥6 weeks (schizophrenia) or ≥3 weeks (bipolar disorder). Findings related to effectiveness (treatment discontinuation, quality of life, and neurocognitive improvements) were generally consistent with those observed in non-Chinese populations. No new safety signals specific for Chinese populations were raised for olanzapine. CONCLUSION: Chinese and non-Chinese populations with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses. Differences between these populations, especially in relation to the relative efficacy of olanzapine versus other antipsychotics, may warrant further investigation via studies incorporating both populations. Use of local data to provide evidence for practice guidelines should be encouraged, and may promote ongoing improvements in the quality of research and study reporting.
format Online
Article
Text
id pubmed-4037301
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-40373012014-05-29 Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review Xue, Hai Bo Haber Liu, Li Zhang, Hena Montgomery, William Treuer, Tamás Neuropsychiatr Dis Treat Review BACKGROUND: Despite the burden of schizophrenia and bipolar disorder in the Chinese population, country-specific data to guide practitioners regarding antipsychotic therapy are lacking. The primary aim of this systematic review was to examine evidence of the efficacy, effectiveness, and safety of olanzapine in Chinese populations. METHODS: A systematic literature search was conducted using databases covering international and Chinese core journals using search terms related to schizophrenia and bipolar disorder, specified countries (People’s Republic of China, Hong Kong, Taiwan), and olanzapine treatment. Following initial screening, inclusion and exclusion criteria were applied to the search results to identify relevant studies from which data were extracted. RESULTS: A total of 489 publications were retrieved and 61 studies were identified for inclusion. Most studies were related to schizophrenia (n=54), with six studies related to bipolar disorder and one study related to both conditions. The quality of study methods and reporting in international journals was noticeably better than in Chinese language journals. Most studies included relatively small patient populations and were of short duration. The efficacy of olanzapine in Chinese populations was confirmed by multiple comparative and noncomparative studies that found statistically significant reductions in symptom measures in studies conducted for ≥6 weeks (schizophrenia) or ≥3 weeks (bipolar disorder). Findings related to effectiveness (treatment discontinuation, quality of life, and neurocognitive improvements) were generally consistent with those observed in non-Chinese populations. No new safety signals specific for Chinese populations were raised for olanzapine. CONCLUSION: Chinese and non-Chinese populations with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses. Differences between these populations, especially in relation to the relative efficacy of olanzapine versus other antipsychotics, may warrant further investigation via studies incorporating both populations. Use of local data to provide evidence for practice guidelines should be encouraged, and may promote ongoing improvements in the quality of research and study reporting. Dove Medical Press 2014-05-16 /pmc/articles/PMC4037301/ /pubmed/24876777 http://dx.doi.org/10.2147/NDT.S58096 Text en © 2014 Xue et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Xue, Hai Bo Haber
Liu, Li
Zhang, Hena
Montgomery, William
Treuer, Tamás
Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review
title Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review
title_full Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review
title_fullStr Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review
title_full_unstemmed Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review
title_short Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review
title_sort olanzapine in chinese patients with schizophrenia or bipolar disorder: a systematic literature review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037301/
https://www.ncbi.nlm.nih.gov/pubmed/24876777
http://dx.doi.org/10.2147/NDT.S58096
work_keys_str_mv AT xuehaibohaber olanzapineinchinesepatientswithschizophreniaorbipolardisorderasystematicliteraturereview
AT liuli olanzapineinchinesepatientswithschizophreniaorbipolardisorderasystematicliteraturereview
AT zhanghena olanzapineinchinesepatientswithschizophreniaorbipolardisorderasystematicliteraturereview
AT montgomerywilliam olanzapineinchinesepatientswithschizophreniaorbipolardisorderasystematicliteraturereview
AT treuertamas olanzapineinchinesepatientswithschizophreniaorbipolardisorderasystematicliteraturereview